Technical Analysis for VYNE - VYNE Therapeutics Inc. - Common Stock

Grade Last Price % Change Price Change
F 5.46 -3.19% -0.18
VYNE closed down 3.19 percent on Thursday, April 15, 2021, on 49 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical VYNE trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -3.19%
Inside Day Range Contraction -3.19%
Wide Bands Range Expansion -3.19%
Oversold Stochastic Weakness -3.19%
Lower Bollinger Band Walk Weakness -3.02%
Wide Bands Range Expansion -3.02%
Older End-of-Day Signals for VYNE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Trending on StockTwits about 6 hours ago
Down 3% about 17 hours ago
Lower Bollinger Band Support about 19 hours ago
60 Minute Opening Range Breakdown about 19 hours ago
Down 2 % about 19 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


VYNE Therapeutics Inc. - Common Stock Description

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is headquartered in Bridgewater, New Jersey.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Autoimmune Diseases Psoriasis Dermatology Dermatitis Acne Atopic Dermatitis Rosacea Pruritus Acne Vulgaris Prurigo Prurigo Nodularis

Is VYNE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 13.1624
52 Week Low 4.84
Average Volume 1,754,951
200-Day Moving Average 7.12
50-Day Moving Average 7.84
20-Day Moving Average 6.60
10-Day Moving Average 6.19
Average True Range 0.46
ADX 41.55
+DI 8.60
-DI 33.58
Chandelier Exit (Long, 3 ATRs ) 6.48
Chandelier Exit (Short, 3 ATRs ) 6.75
Upper Bollinger Band 7.82
Lower Bollinger Band 5.38
Percent B (%b) 0.03
BandWidth 37.04
MACD Line -0.52
MACD Signal Line -0.43
MACD Histogram -0.0839
Fundamentals Value
Market Cap 916.62 Million
Num Shares 168 Million
Price-to-Sales 9.45
Price-to-Book 5.73
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.97
Resistance 3 (R3) 6.00 5.86 5.89
Resistance 2 (R2) 5.86 5.73 5.84 5.86
Resistance 1 (R1) 5.66 5.65 5.59 5.63 5.83
Pivot Point 5.52 5.52 5.48 5.50 5.52
Support 1 (S1) 5.32 5.39 5.25 5.29 5.09
Support 2 (S2) 5.18 5.31 5.16 5.06
Support 3 (S3) 4.98 5.18 5.04
Support 4 (S4) 4.95